Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Nateraâs complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications. Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Companyâs own robust laboratory processes thousands of genetic tests per month. Nateraâs goal is to transform the way people â both providers and patients â respond to and manage genetic diseases. Source
No articles found.
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...
Ultragenyx is a biopharmaceutical company commi...
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...
For more than 40 years, IntriCon has been meeti...
We make affordable assistive products, starting with a groundbreaking supportive w...
We make affordable assistive products, starting...
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses o...
Aeolus Pharmaceuticals, Inc. is a biopharmaceut...
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...
GenMark Diagnostics (NASDAQ: GNMK) is a leading...
Join the National Investor Network and get the latest information with your interests in mind.